These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 30714167)

  • 1. Plasma Epstein-Barr virus DNA as an archetypal circulating tumour DNA marker.
    Lam WKJ; Chan KCA; Lo YMD
    J Pathol; 2019 Apr; 247(5):641-649. PubMed ID: 30714167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequencing-based counting and size profiling of plasma Epstein-Barr virus DNA enhance population screening of nasopharyngeal carcinoma.
    Lam WKJ; Jiang P; Chan KCA; Cheng SH; Zhang H; Peng W; Tse OYO; Tong YK; Gai W; Zee BCY; Ma BBY; Hui EP; Chan ATC; Woo JKS; Chiu RWK; Lo YMD
    Proc Natl Acad Sci U S A; 2018 May; 115(22):E5115-E5124. PubMed ID: 29760067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical utility of circulating Epstein-Barr virus DNA analysis for the management of nasopharyngeal carcinoma.
    Fung SY; Lam JW; Chan KC
    Chin Clin Oncol; 2016 Apr; 5(2):18. PubMed ID: 27121878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of plasma Epstein-Barr virus DNA load to distinguish nasopharyngeal carcinoma patients from healthy high-risk populations in Southern China.
    Ji MF; Huang QH; Yu X; Liu Z; Li X; Zhang LF; Wang P; Xie SH; Rao HL; Fang F; Guo X; Liu Q; Hong MH; Ye W; Zeng YX; Cao SM
    Cancer; 2014 May; 120(9):1353-60. PubMed ID: 24477877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Negative plasma Epstein-Barr virus DNA nasopharyngeal carcinoma in an endemic region and its influence on liquid biopsy screening programmes.
    Nicholls JM; Lee VH; Chan SK; Tsang KC; Choi CW; Kwong DL; Lam KO; Chan SY; Tong CC; So TH; Leung TW; Luk MY; Khong PL; Lee AW
    Br J Cancer; 2019 Oct; 121(8):690-698. PubMed ID: 31527689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Noninvasive diagnosis of nasopharyngeal carcinoma: nasopharyngeal brushings reveal high Epstein-Barr virus DNA load and carcinoma-specific viral BARF1 mRNA.
    Stevens SJ; Verkuijlen SA; Hariwiyanto B; Harijadi ; Paramita DK; Fachiroh J; Adham M; Tan IB; Haryana SM; Middeldorp JM
    Int J Cancer; 2006 Aug; 119(3):608-14. PubMed ID: 16572427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical utility of Epstein-Barr virus DNA and other liquid biopsy markers in nasopharyngeal carcinoma.
    Tan R; Phua SKA; Soong YL; Oon LLE; Chan KS; Lucky SS; Mong J; Tan MH; Lim CM
    Cancer Commun (Lond); 2020 Nov; 40(11):564-585. PubMed ID: 32989921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
    Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
    Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved risk stratification of nasopharyngeal cancer by targeted sequencing of Epstein-Barr virus DNA in post-treatment plasma.
    Chan DCT; Lam WKJ; Hui EP; Ma BBY; Chan CML; Lee VCT; Cheng SH; Gai W; Jiang P; Wong KCW; Mo F; Zee B; King AD; Le QT; Chan ATC; Chan KCA; Lo YMD
    Ann Oncol; 2022 Aug; 33(8):794-803. PubMed ID: 35491007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early detection of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA analysis in a surveillance program.
    Chan KC; Hung EC; Woo JK; Chan PK; Leung SF; Lai FP; Cheng AS; Yeung SW; Chan YW; Tsui TK; Kwok JS; King AD; Chan AT; van Hasselt AC; Lo YM
    Cancer; 2013 May; 119(10):1838-44. PubMed ID: 23436393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of plasma Epstein-Barr virus DNA level during posttreatment follow-up in the patients with nasopharyngeal carcinoma having undergone intensity-modulated radiotherapy.
    Li WF; Zhang Y; Huang XB; Du XJ; Tang LL; Chen L; Peng H; Guo R; Sun Y; Ma J
    Chin J Cancer; 2017 Nov; 36(1):87. PubMed ID: 29116021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epstein-Barr virus mRNA profiles and viral DNA methylation status in nasopharyngeal brushings from nasopharyngeal carcinoma patients reflect tumor origin.
    Ramayanti O; Juwana H; Verkuijlen SA; Adham M; Pegtel MD; Greijer AE; Middeldorp JM
    Int J Cancer; 2017 Jan; 140(1):149-162. PubMed ID: 27600027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Epstein-Barr virus DNA level in plasma, peripheral blood cell and tumor tissue in nasopharyngeal carcinoma.
    Shao JY; Zhang Y; Li YH; Gao HY; Feng HX; Wu QL; Cui NJ; Cheng G; Hu B; Hu LF; Ernberg I; Zeng YX
    Anticancer Res; 2004; 24(6):4059-66. PubMed ID: 15736452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylation analysis of plasma DNA informs etiologies of Epstein-Barr virus-associated diseases.
    Lam WKJ; Jiang P; Chan KCA; Peng W; Shang H; Heung MMS; Cheng SH; Zhang H; Tse OYO; Raghupathy R; Ma BBY; Hui EP; Chan ATC; Woo JKS; Chiu RWK; Lo YMD
    Nat Commun; 2019 Jul; 10(1):3256. PubMed ID: 31332191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical relevance of plasma EBV DNA as a biomarker for nasopharyngeal carcinoma in non-endemic areas: A multicenter study in southwestern China.
    He Q; Zhou Y; Zhou J; Zhao D; Li L; Li X; Huang Y; Wang Q; Zou H; Zhang K; Li Y; Wang Z; Deng Y; Meng F; Ying B; Yang M; Wang D
    Clin Chim Acta; 2023 Feb; 541():117244. PubMed ID: 36746264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical applications of plasma Epstein-Barr virus DNA analysis and protocols for the quantitative analysis of the size of circulating Epstein-Barr virus DNA.
    Chan KC; Lo YM
    Methods Mol Biol; 2006; 336():111-21. PubMed ID: 16916257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a non-endemic area.
    Alfieri S; Iacovelli NA; Marceglia S; Lasorsa I; Resteghini C; Taverna F; Mazzocchi A; Orlandi E; Guzzo M; Bianchi R; Fanti D; Pala L; Racca S; Dvir R; Quattrone P; Gloghini A; Volpi CC; Granata R; Bergamini C; Locati L; Licitra L; Bossi P
    Oncotarget; 2017 Jul; 8(29):47780-47789. PubMed ID: 28562354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating Epstein-Barr virus microRNAs miR-BART7 and miR-BART13 as biomarkers for nasopharyngeal carcinoma diagnosis and treatment.
    Zhang G; Zong J; Lin S; Verhoeven RJ; Tong S; Chen Y; Ji M; Cheng W; Tsao SW; Lung M; Pan J; Chen H
    Int J Cancer; 2015 Mar; 136(5):E301-12. PubMed ID: 25213622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma Epstein-Barr virus DNA as a biomarker for nasopharyngeal carcinoma.
    Chan KC
    Chin J Cancer; 2014 Dec; 33(12):598-603. PubMed ID: 25418194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epstein-Barr virus biomarkers for nasopharyngeal carcinoma in non-endemic regions.
    Gurtsevitch VE; Senyuta NB; Ignatova AV; Lomaya MV; Kondratova VN; Pavlovskaya AI; Dushenkina TE; Maximovich DM; Smirnova KV; Mudunov AM; Lichtenstein AV
    J Gen Virol; 2017 Aug; 98(8):2118-2127. PubMed ID: 28786806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.